xii
DAFTAR PUSTAKA
Al Quran dan Terjemahnya. 2009. Kementerian Agama Republik Indonesia.
Jakarta: Halim.
Aidh bin Abdullah. 2005. Dont be Sad, La tahzan, Cara Hidup Positif Tanpa Pernah Sedih dan Frustrasi. Maghfirah Pustaka. Jakarta.
Archer Melisa dan Oderda Gary. 2013. Teriflunomide (Aubagio) Drug Review.
University of Utah College of Pharmacy, pp 3-9.
Cohen JA, Coles AJ, Arnold DL, et al. 2012. Alemtuzumab Versus Interferon Beta 1a as First-line Treatment for Patients with Relapsing_remitting Multiple Sclerosis: A Randomised Controlled Phase 3 Trial. Lancet, 380, pp 1819–1828.
Coles AJ, Twyman CL, Arnold DL, et al. 2012. Alemtuzumab for Patients with Relapsing Multiple Sclerosis After Disease-modifying Therapy: A Randomised Controlled Phase 3 Trial. Lancet 2012, 380, pp 1829–1839.
Confavreux Christian, O’Connor Paul, Comi Giancarlo, et al. 2014. Oral
Teriflunomide for Patients with Relapsing Multiple Sclerosis (TOWER): A Randomised, Double-blind, Placebo Controlled, Phase 3 Trial. Lancet Neurology, 13, pp 247-256
D He, Z Hu, S Dong, et al. 2012. Teriflunomide for Multiple Sclerosis (Review).
The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd. Issue 12.
Dhib-Jalbut S dan Marks S. 2010. Interferon-b Mechanisms of Action in Multiple Sclerosis. Neurology, 74(Suppl.1), pp 17-24.
Food Drug Administration. 2012. Teriflunomide.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.p df Diunduh tanggal 6 Maret 2016 jam 13.00 WIB.
Freedman Mark S. 2013. Teriflunomide in Relapsing Multiple Sclerosis:
Therapeutic Utility. Department of Medicine (Neurology) University of Ottawa, 4(5), pp 192-205
H Noda, Takeuchi H, Mizuno T, Suzumura A. et al. 2013. Fingolimod Phosphate Promotes the Neuroprotective Effects of microglia. J Neuroimmunol, 256, pp 13-18.
xiii
Genzyme Corporation (2012) Aubagio Prescribing Information. Cambridge, MA:
Genzyme Corporation
Greenberg David A, Aminoff Michael J, Simon Roger P. 2012. Clinical Neurology. International edition Mc Graw Hill Lange.
Ginsberg Lionel. 2007. Neurologi. Penerbit Erlangga, pp 143-150.
Gold R. dan Wolinsky J. 2011. Pathophysiology of Multiple Sclerosis and the Place of Teriflunomide. Acta Neurol Scand, 124, pp 75–84.
Kappos L, Radue EW, O’Connor P, et al. 2010. A Placebo Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N Engl J Med, 362, 387401.
Limsakun T dan Menguy-Vacheron F. 2010. Pharmacokinetics of Oral
Teriflunomide, a Novel Oral Disease-modifying Agent Under Investigation for the Treatment of Multiple Sclerosis. In: Proceedings of the 62nd Annual Meeting of the American Academy of Neurology.
Linker dan Gold. 2013. Dimethyl Fumarate for Treatment of Multiple Sclerosis:
mechanism of action, effectiveness, and side effects. Curr Neurol Neurosci Rep, 13: 394.
Loma, I. dan Heyman, R. (2011) Multiple sclerosis: Pathogenesis and Treatment.
Curr Neuropharmacol 9, pp 409–416.
Luzzio, C. 2015. Multiple Sclerosis. www.emedicine.com. Diunduh tanggal 5 Maret 2016 jam 20.00 WIB.
Marriot JJ, Miyasaki, Gronseth, O’Connor. 2010. Evidence Report: The efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 74(18), pp 1463-1470.
Miller A, Turpault S, dan Menguy-Vacheron F. 2012. Rapid Elimination Procedure of Teriflunomide with Cholestyramine or Activated Charcoal. In Fourth Cooperative Meeting of CMSC and ACTRIMS, 30 May–2 June 2012, San Diego, CA, USA, P10.
Mumenthaler Mark, Mattle Heirich, Taub Ethan. 2006. Fundamental of Neurology. Thieme.
xiv
O’Connor Paul, Wolinsky Jerry S, Confavreux Christian, et al. 2012. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis. The New England Journal of Medicine, 365, 1293-1303
Oh dan O’conor. 2014. Teriflunomide in the Treatment of Multiple Sclerosis:
Current Evidence and Future Prospects. Ther Adv Neurol Disord, 7(5) 239–
252. Reprints and permissions: http://www.sagepub.co.uk/
Polman CH, O’Connor PW, Havrdova E, et al. 2006. A randomized, Placebo- controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. N Engl J Med, 354, pp 899–910.
Racke Michael dan Lovett-Racke Amy. 2011. Glatiramer Acetate Treatment of Multiple Sclerosis: An Immunological Perspective. The Journal of Immunology, 186, pp 1887-1890.
Rohkamm Reinhard. 2004. Color Atlas of Neurology. Thieme.
Taslim Abdullah. 2010. Sikap Seorang Muslim dalam Menghadapi Musibah.
https://muslim.or.id/5026-sikap-seorang-muslim-dalam-menghadapi- musibah.html. Diakses pada tanggal 5 maret 2016. Jam 07.00.
Torkildsen, Myhr, et al. 2015. Disease-modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology 2015, 23 (Suppl. 1): 18–27
Wang L, Van Horn R, Turpault S, dan Zeng Z. 2011. Metabolism comparison between leflunomide and teriflunomide in humans. Eur J Neurol 18(Suppl.
2), 268.
Warnke Clements, Kiesier Bernds C, Stuve olaf. 2013. Teriflunomide for the treatment of multiple sclerosis. Clinical Neurology and Neurosurgery, 115S, pp S90– S94. Journal homepage: www.elsevier.com/locate/clineuro
Wibowo, A. 2012. Maqoshid Asy Syariah: The Ultimate Objective of Syariah.
Diunduh dari: www. staff.uny.ac.id. Diakses tanggal 5 Maret 2016. Jam 07.00
Wu GF dan Alvarez E. The immuno-pathophysiology of multiple sclerosis.
Neurol Clin. 2011 May ; 29(2), pp 257-78.
Zuhroni et al. 2003. Islam Untuk Ilmu Kesehatan dan Kedokteran 2 (Fiqh Kontemporer). Departemen Agama RI Direktorat Jendral Kelembagaan Agama Islam. Jakarta.
xv
Zuhroni. 2010. Dasar dan Sumber Syariat Islam. Jakarta. Bagian Agama Islam Universitas Yarsi
